Insmed (INSM) falls 18% premarket after reporting the results of a Phase 3 trial for Arikace. Although the treatment achieved the primary non-inferiority endpoint, it appears Arikace did not show as well as tobramycin inhalation solution in terms of FEV1 (see presentation, slide 3).
Insmed (INSM) falls 18% premarket after reporting the results of a Phase 3 trial for Arikace....
From other sites
at CNBC.com (Jun 18, 2014)
at CNBC.com (Mar 26, 2014)
at CNBC.com (Oct 27, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs